Streetbeat News

Regulatory

CTRM

Castor Maritime has regained compliance with the Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 1:16 pm

CRBU

Caribou Biosciences, Inc. (NASDAQ:CRBU), a leader in CRISPR genome-editing biopharmaceuticals, announced its presentation on Cas12a chRDNA genome-editing for hepatic gene disruption at ASGCT's 27th annual meeting in May 2024. The presentation will highlight the efficiency and functionality of Caribou's novel CRISPR platform, which offers more precise genome editing by using hybrid RNA-DNA guides (chRDNAs) to reduce off-target effects.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 1:15 pm

MOH

Molina Healthcare's stock is trading lower following the announcement of the Statewide Medicaid Managed Care Program awards in Florida, from which the company was reportedly excluded.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 1:12 pm

SPY

Federal Reserve Bank of New York President John Williams indicated that the Federal Reserve is likely to start lowering interest rates this year, contingent on the continued gradual decrease of inflation. Williams expressed confidence in the current state of monetary policy, highlighting the enduring strength of consumers.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 1:09 pm

RNAZ

TransCode Therapeutics has received FDA clearance to begin a Phase 1/2 clinical trial with TTX-MC138 for treating patients with advanced solid tumors. This marks a significant step forward in the company's development pipeline and could potentially impact its stock price positively in the short term as investors react to the news of the trial's approval.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 1:03 pm

AA

CENX

KALU

RIO

Metals stocks, including AA, CENX, KALU, and RIO, are trading higher after sanctions were imposed banning the delivery of Russian metals on the London Metal Exchange.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:57 pm

HOOK

RHHBY

RPTX

Roche Holdings AG announced positive Phase 3 results for its lymphoma drug Columvi in combination with chemotherapy, showing extended survival in pretreated patients with diffuse large B-cell lymphoma. The study met its primary endpoint of overall survival. Columvi, a bispecific antibody, previously received FDA accelerated approval for this patient group after two or more lines of systemic therapy. Additionally, Roche terminated two cancer drug deals earlier this year with Repare Therapeutics and HOOKIPA Pharma.

Portfolio Pulse from Vandana Singh

April 15, 2024 | 12:56 pm

USAU

U.S. Gold Corp. (USAU) has announced a registered direct offering and concurrent private placement of shares and warrants, aiming to raise approximately $4.9 million. The offering includes 1,400,000 shares at $3.50 each and warrants for an additional 1,400,000 shares at $4.48 each. The closing is expected around April 19, 2024, with common stock offered under a previously filed SEC registration statement.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:42 pm

DJT

Trump Media & Technology Group Corp has filed with the SEC to allow selling securityholders to sell up to 146.1 million shares of common stock from time to time.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:38 pm

ICCM

IceCure Medical announced the final results of its ICE3 breast cancer cryoablation trial, submitting data to the FDA for marketing authorization to treat early-stage breast cancer. The data, presented at the ASBrS Annual Meeting and awarded the Scientific Impact Award, supports the use of cryoablation for early stage T1 invasive breast cancer with adjuvant hormone therapy. The company anticipates enhanced usage upon approval, citing the availability of a reimbursement code for facility expenses and the cost-effectiveness of its ProSense® cryoablation system.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:37 pm